Cover Image

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Umberto Restelli,1,2 Massimiliano Fabbiani,3 Simona Di Giambenedetto,3 Carmela Nappi,4 Davide Croce,1,2 1Centre for Research on Health Economics, Social and Health Care Management (CREMS), LIUC – Università Cattaneo, Castellanza, Italy; 2School of Public Health, Faculty of Healt...

Full description

Saved in:

Bibliographic Details
Main Authors:	Restelli U (Author), Fabbiani M (Author), Di Giambenedetto S (Author), Nappi C (Author), Croce D (Author)
Format:	Book
Published:	Dove Medical Press, 2017-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]
by: Restelli U, et al.
Published: (2017)

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
by: Restelli U, et al.
Published: (2017)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
by: Miriam Samuel, et al.
Published: (2014)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
by: Christiana Smith, et al.
Published: (2016)

Atazanavir/Ritonavir Increased Tizoxanide Exposure from Oral Nitazoxanide through Pharmacokinetic Interaction in Healthy Volunteers
by: Abdulafeez Akinloye, et al.
Published: (2024)

Physiologically based pharmacokinetic modeling of drug-drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy
by: Shakir Atoyebi, et al.
Published: (2024)

Role of atazanavir in the treatment of HIV infection
by: Pablo Rivas, et al.
Published: (2008)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019)

A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents
by: Bernard Ngara, et al.
Published: (2020)

Study of atazanavir-induced hyperbilirubinemia among HIV patients on second-line anti-retroviral therapy
by: K Ravi, et al.
Published: (2020)

Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV
by: Sikiru Olatunji Usman, et al.
Published: (2022)

The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial
by: Sima Ramezaninejad, et al.
Published: (2023)

Registro, incorporação tecnológica e produção pública de medicamento: estudo sobre o atazanavir | Registration, technology adoption and public production of a medicine: study of atazanavir
by: Carla Cristina de Freitas da Silveira, et al.
Published: (2016)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
by: Lozano R, et al.
Published: (2013)

Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
by: Restelli U, et al.
Published: (2014)

Estratégia de proteção de patentes farmacêuticas: o caso do atazanavir
by: Carla Cristina de Freitas da Silveira, et al.
Published: (2016)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
by: Lozano R, et al.
Published: (2013)

Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe
by: Bernard Ngara, et al.
Published: (2021)

Atazanavir efficacy in covid-19: A retrospective protease inhibitors comparative study 2020
by: Ahmad Alikhani, et al.
Published: (2022)

Registro, incorporação tecnológica e produção pública de medicamento: estudo sobre o atazanavir
by: Carla Cristina de Freitas da Silveira, et al.
Published: (2016)

Registro, incorporação tecnológica e produção pública de medicamento: estudo sobre o atazanavir
by: Carla Cristina de Freitas da Silveira, et al.
Published: (2016)

Registro, incorporação tecnológica e produção pública de medicamento: estudo sobre o atazanavir
by: Carla Cristina de Freitas da Silveira, et al.
Published: (2016)

Development and validation of a stability-indicating RP-HPLC method for estimation of atazanavir sulfate in bulk
by: S. Dey, et al.
Published: (2017)

Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review
by: Laura Saint-Lary, et al.
Published: (2022)

Interactions between Phytochemical Components of Sutherlandia Frutescens and the Antiretroviral, Atazanavir In Vitro: Implications for Absorption and Metabolism
by: Adrienne C Müller, et al.
Published: (2012)

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
by: Panagopoulos P, et al.
Published: (2017)

Indinavir and atazanavir; comparison of predicted property by chemoinformatics technique and implication on renal problem in HIV infected patients
by: Beuy Joob, et al.
Published: (2017)

Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS
by: Saif Ahmad Khan, et al.
Published: (2020)

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
by: Naidoo A, et al.
Published: (2017)

Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M<sup>pro</sup>, Impairing Variants Replication In Vitro and In Vivo
by: Otávio Augusto Chaves, et al.
Published: (2021)

Niveles de perfil lipídico en pacientes con VIH-sida en tratamiento con efavirenz y atazanavir. Estudio de cohorte
by: Fernando Geldres-Molina, et al.
Published: (2021)

Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy
by: Daniela Poblete, et al.
Published: (2021)

EVOLUÇÃO DA GRAVIDADE DOS SINTOMAS DE PACIENTES COM COVID-19 TRATADOS COM ATAZANAVIR E IVERMECTINA: estudo de coorte prospectivo
by: Francisco Braz Milanez Oliveira, et al.
Published: (2023)

Registro, incorporaÃ§Ã£o tecnolÃ³gica e produÃ§Ã£o pÃºblica de medicamento: estudo sobre o atazanavir
by: Carla Cristina de Freitas da Silveira, et al.
Published: (2016)

Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters
by: Thirumal Eswara Goud, et al.
Published: (2016)

Identification of Mechanism and Pathway of the Interaction between the African Traditional Medicine, Sutherlandia Frutescens, and the Antiretroviral Protease Inhibitor, Atazanavir, in Human Subjects Using Population Pharmacokinetic (PK) Analysis
by: Adrienne Carmel Muller, et al.
Published: (2018)

Simplification of HAART therapy on ambulatory HIV patients in Malaysia: a randomized controlled trial
by: Velvanathan T, et al.
Published: (2016)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
by: Vincenzo Russo, et al.
Published: (2020)

Protocol Implementation for Normothermia in Surgery Settings in Italy: Budget-Impact Analysis
by: Monzani R, et al.
Published: (2020)

Tax simplification - An African Perspective
by: Riël Franzsen
Published: (2019)